<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">Exogenous estrogen and testosterone therapies have a therapeutic potential to mitigate the damaging inflammatory response to SARS-CoV-2 without hampering the immune system’s response to the virus as corticosteroids do.
 <xref rid="bib33" ref-type="bibr">
  <sup>33</sup>
 </xref> Recently, investigators have suggested the use of immune-modulating drugs to block inflammatory markers’ receptors to mitigate the amplified and tissue-damaging immune response of SARS-CoV-2 (eg, anarka [an IL-1 receptor blocker] and tocilizumab and sarilumab [IL-6 receptor antagonists]).
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib33" ref-type="bibr">
  <sup>33</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib34" ref-type="bibr">
  <sup>34</sup>
 </xref> However, there are concerns about these agents’ possible adverse effects on patients’ immune function.
</p>
